(Reuters) – The U.S. Food and Drug Administration granted full approval to Swedish drugmaker Calliditas Therapeutics’ drug to treat rare kidney disease IgA Nephropathy, the company said on Wednesday.
(Reporting by Mariam Sunny, Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Shinjini Ganguli)
